Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
Клинические исследования пероральных, ингаляционных и внутривенных систем доставки лекарственных средств для лечения рака лёгкого и новые подходы на основе наномедицины
2023-12-01
SCID: 54.1/48zbsp25
Discuss with AI
clinical trialsdrug delivery systemslung cancernanomedicinetargeted therapy
Figures from the paper
Abstract (AI)
Abstract: Lung cancer is one of the most common malignant tumors worldwide and is characterized by high morbidity and mortality rates and a poor prognosis. It is the leading cause of cancer-related death in the United States and worldwide. Most patients with lung cancer are treated with chemotherapy, radiotherapy, or surgery; however, effective treatment options remain limited. In this review, we aim to provide an overview of clinical trials, ranging from Phase I to III, conducted on drug delivery systems for lung cancer treatment. The trials included oral, inhaled, and intravenous administration of therapeutics. Furthermore, the study also talks about the evolving paradigm of targeted therapy and immunotherapy providing promising directions for personalized treatment. In addition, we summarize the best results and limitations of these drug delivery systems and discuss the potential capacity of nanomedicine. Keywords: lung cancer, clinical trials, nanomedicine, oral, intravenous, inhalation
Key Findings
1
Current lung cancer management relies mainly on chemotherapy, radiotherapy, and surgery, but effective treatment options remain limited despite high disease mortality.
2
Targeted therapy and immunotherapy are emerging as promising approaches for more personalized lung cancer treatment.
3
The review summarizes reported benefits and limitations of existing drug-delivery systems and assesses nanomedicine’s potential for lung cancer therapy.
4
The review surveys Phase I–III clinical trials evaluating oral, inhaled, and intravenous drug-delivery systems for lung cancer treatment.
Research Object
Drug delivery systems for lung cancer treatment, including oral, inhaled, and intravenous therapeutic administration
Research Subject
Clinical-trial evidence, outcomes, limitations, and emerging nanomedicine-based approaches for these delivery systems, including targeted therapy and immunotherapy
Publication Details
Publication Date
2023-12-01
Journal
Publisher
ISSN
Cited by
30
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest